LivaNova
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardi...
Latest News
4 days ago · seekingalpha.com
LivaNova: Paying Off The Last Legacy Bill Just As The Sleep Apnea Market Opens UpLivaNova PLC is rapidly transitioning into a 'clean compounder' with strong growth prospects and legacy liabilities nearly resolved. LIVN raised 2026 guidance to 9-10% revenue growth and 14% adjusted EPS growth, driven by cardiopulmonary and neuromodulation segments. Oxygenator demand exceeds supply, with LIVN gaining market share and expanding production capacity, while OSA entry is poised for favorable reimbursement tailwinds.
8 days ago · seekingalpha.com
LivaNova PLC (LIVN) Presents at 2026 UBS Global Healthcare Conference TranscriptLivaNova PLC ( LIVN ) 2026 UBS Global Healthcare Conference November 9, 2026 11:00 AM EST Company Participants Alex Shvartsburg - Chief Financial Officer Philip Kowalczyk - Chief Strategy & Corporate Development Officer Conference Call Participants Benjamin Bible Presentation Benjamin Bible Welcome. With me today is Alex Shvartsburg and Philip Kowalczyk, CFO and Head of Strategy and EVP from LivaNova.
13 days ago · seekingalpha.com
LivaNova PLC (LIVN) Q3 2026 Earnings Call TranscriptLivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript
13 days ago · marketbeat.com
LivaNova Q3 Earnings Call HighlightsLivaNova NASDAQ: LIVN reported third-quarter 2026 revenue growth of 10% from the prior-year period, driven by double-digit gains in its Cardiopulmonary and epilepsy businesses. The medical technology company raised its full-year revenue and adjusted earnings outlook, citing commercial execution, healthy demand and progress in manufacturing capacity expansion.
13 days ago · zacks.com
LivaNova (LIVN) Reports Q3 Earnings: What Key Metrics Have to SayThe headline numbers for LivaNova (LIVN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
13 days ago · zacks.com
LivaNova (LIVN) Surpasses Q3 Earnings and Revenue EstimatesLivaNova (LIVN) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.11 per share a year ago.
13 days ago · businesswire.com
LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS GuidanceGLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) Third-quarter revenue of $393.1 million increased 9.9% on a reported basis and 10.0% on a constant-currency basis as compared to the prior-year period Third-quarter U.S. GAAP diluted earnings per share of $0.11 and adjusted diluted earnings per.
25 days ago · businesswire.com
Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant EpilepsyGLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Neuromodulation: Technology at the Neural Interface has published the full 36-month results from the CORE-VNS study, the first long-term effectiveness evaluation of contemporary VNS Therapy™ devices in people with Drug-Resistant Epilepsy (DRE). The article, “CORE-VNS Seizure and Non-Seizure 36 Month Outcomes in People with Drug-resistant Epilepsy,”1 re.
2 months ago · seekingalpha.com
LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptLivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
2 months ago · fool.com
LivaNova Director Sells 1,650 Shares for $131,500The sale was valued at approximately $131,500. The shares traded were equal to 17% of the director's equity stake held directly before the filing.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove LIVN